CytoTools AG received notification from its license partner Centaur Pharmaceuticals Pvt Ltd. (Mumbai, India) of the start of marketing of its wound healing active substance DPOCL which is currently still in the approval process in Europe under the name DermaPro(R). Following the successful approval of the active ingredient by the India Central Drugs Standard Control Organization (CDSCO) and the GMP certification of the production in October 2019, the marketing of the drug will now start in the Indian market under the brand name WOXheal. The market launch of WOXheal will therefore start primarily through video and telephone conferences with selected key opinion leaders in the field of diabetes. The conferences are held in cooperation with leading hospitals in the country. Depending on the extent of the applicable travel restrictions, opinion leaders will also be addressed personally via pharmaceutical representatives of the licensing partner. At market launch, Woxheal will be distributed directly through the partner clinics' affiliated pharmacies. The connection of further clinics and pharmacies is currently being established and will be implemented consistently. Starting in mid-September, patient information on the effects and the use of the drug will also be made available online via the domain www.woxheal.com. Media marketing is also carried out via radio and advertising campaigns. WOXheal is sold in India in packaging sizes that cover the daily requirements of a patient with average symptoms for about one week. Based on the clinical studies, full recovery with average symptoms occurs after three to eight weeks. The market price of the weekly package of WOXheal is currently around EUR 20.